In VivoTransfer Efficiency of Antisense Oligonucleotides into the Myocardium Using HVJ–Liposome Method
- 1 February 1997
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 231 (3) , 540-545
- https://doi.org/10.1006/bbrc.1996.5762
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.Proceedings of the National Academy of Sciences, 1995
- Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene.Proceedings of the National Academy of Sciences, 1995
- Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome deliveryGene, 1994
- Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial InjuryScience, 1994
- Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides.Journal of Clinical Investigation, 1994
- Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.Proceedings of the National Academy of Sciences, 1993
- Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivoNature, 1992
- Human gene therapy comes of ageNature, 1992
- Human gene therapyScience, 1992
- Increased Expression of DNA Cointroduced with Nuclear Protein in Adult Rat LiverScience, 1989